News &amp; Updates

High consumption of red meat appears to increase the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), but only in men, particularly at intake levels ranging from 75 to 90 g/day, reveals a recent study.

Is red meat a risk factor for MASLD?

08 Apr 2026

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

Initiation of an SGLT2 inhibitor, relative to a GLP-1 receptor agonist (RA), results in a lower risk of adverse kidney events among patients with stage 2 diabetes and stage 4‒5 chronic kidney disease (CKD), with similar cardiovascular and mortality risks, a study has shown.

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients

08 Apr 2026

ORP-101 for IBS with diarrhoea misses mark in phase II trial

The novel partial μ receptor agonist and full κ receptor antagonist ORP-101 has failed to demonstrate superiority to placebo in the treatment of patients with irritable bowel syndrome (IBS) with diarrhoea (IBS-D) in a phase II randomized controlled trial.

ORP-101 for IBS with diarrhoea misses mark in phase II trial

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

Tavapadon, a novel, investigational, selective D1/D5 agonist with once-daily oral dosing, provides clinically meaningful and sustained benefit adjunctive to levodopa and has a favourable safety profile in patients with Parkinson’s disease (PD) experiencing off fluctuations, according to findings of the TEMPO-3 trial.

Tavapadon shows promise as adjunct therapy for Parkinson’s Disease in phase III trial

Increased ischaemic stroke cases during Ramadan

A study conducted in southern Thailand has found a higher incidence of non-recurrent ischaemic stroke among Muslims during the Ramadan period (when Muslims observe a ‘fasting window’ from sunrise to sunset) compared with the rest of the year.

Increased ischaemic stroke cases during Ramadan

$Weight maintenance after smoking cessation lowers fracture risk in men with T2DM$

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

Quitting smoking does not appear to contribute to a decrease in fracture risk in male patients newly diagnosed with type 2 diabetes mellitus (T2DM), but maintaining weight following cessation may help, reveals a study. Moreover, weight loss after quitting tends to increase such risk.

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

07 Apr 2026 by

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a lower risk of developing various incident substance use disorders (SUDs), suggests a study involving US veterans with type 2 diabetes (T2D). Its use also protects against adverse clinical outcome in people with pre-existing SUDs.

GLP-1 RAs may deter substance addiction, SUD-related adverse outcomes

Patient tone influences AI-generated clinical advice in E-medicine

A recent study has shown how large language models (LLMs) treat patient tone as clinical input, leading to adjustments in triage, follow-up, prescribing, and sick-leave decisions despite identical symptoms.

Patient tone influences AI-generated clinical advice in E-medicine